{"gene":"HELZ2","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2002,"finding":"PRIC285 (HELZ2) was identified as a component of a transcriptionally active PPARα-interacting cofactor (PRIC) complex purified from rat liver nuclear extracts. PRIC285 contains five LXXLL motifs, interacts with PPARα, and acts as a coactivator by moderately stimulating PPARα-mediated transcription in transfected cells.","method":"Biochemical purification of nuclear extract complex, mass spectrometry, limited sequence analysis, cDNA cloning, transfection-based reporter assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complex purification with MS identification plus functional reporter assay, single lab, two orthogonal methods","pmids":["12189208"],"is_preprint":false},{"year":2013,"finding":"HELZ2 interacts with THRAP3 (a Mediator complex component) via its helicase motifs; THRAP3 and HELZ2 synergistically enhance PPARγ-mediated transcription, and both are co-recruited to PPARγ-response elements in the Fabp4/aP2 and Adipoq gene enhancers in a ligand-dependent manner in differentiated 3T3-L1 adipocytes.","method":"Yeast two-hybrid, co-immunoprecipitation with mass spectrometry, reporter assay, siRNA knockdown, chromatin immunoprecipitation (ChIP)","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP, reporter assay, and siRNA rescue all converge on the same mechanism; multiple orthogonal methods in a single rigorous study","pmids":["23525231"],"is_preprint":false},{"year":2017,"finding":"HELZ2 functions as an interferon (IFN) antiviral effector (IFN-stimulated gene) against dengue virus; upon IFN stimulation, HELZ2 protein levels increase in the nucleus. HELZ2 interacts with the aryl hydrocarbon receptor (AHR) as identified by co-immunoprecipitation, and HELZ2 knockdown cells are depleted of specific triglyceride subsets. Primary macrophages from HELZ2 knockout mice show enhanced dengue infectivity compared to wild-type controls.","method":"Functional genomic screen (siRNA), co-immunoprecipitation, ChIP-sequencing, mass spectrometry (lipid profiling), HELZ2 knockout mouse macrophage infection assay","journal":"Frontiers in microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse experiment with defined infectious phenotype plus Co-IP and ChIP-seq, single lab, multiple methods","pmids":["28265266"],"is_preprint":false},{"year":2014,"finding":"Helz2 deficiency in mice leads to upregulated hepatic Leprb (long-form leptin receptor) expression, activation of hepatic AMPK, increased fatty acid β-oxidation, and protection from high-fat diet-induced obesity and insulin resistance, establishing HELZ2 as a transcriptional coregulator that suppresses hepatic Leprb expression in vivo.","method":"Helz2 knockout mouse generation and phenotypic analysis, adenovirus-mediated liver-specific Leprb overexpression, calorimetry, gene expression analysis","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with defined metabolic phenotype and rescue experiment (adenoviral Leprb), single lab","pmids":["25004093"],"is_preprint":false},{"year":2021,"finding":"SFPQ associates with tyrosine-phosphorylated HELZ2 as identified by co-immunoprecipitation and mass spectrometry; SFPQ knockdown in 3T3-L1 cells downregulates early adipocyte differentiation transcription factors (Krox20, C/EBPβ, C/EBPδ) and inhibits adipocyte differentiation.","method":"Co-immunoprecipitation of phospho-HELZ2 followed by mass spectrometry, siRNA knockdown, gene expression analysis","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP/MS identification of SFPQ interaction, functional effects attributed to SFPQ knockdown without direct mechanistic link to HELZ2","pmids":["34052659"],"is_preprint":false},{"year":2021,"finding":"HELZ2 interacts with c-Myc and promotes its K63-linked polyubiquitination by facilitating the interaction between c-Myc and E3 ubiquitin ligase HUWE1; this HUWE1-dependent K63-linked ubiquitination activates c-Myc and promotes retinoblastoma cell proliferation and tumorigenesis.","method":"Co-immunoprecipitation, ubiquitination assay (K63-linkage specific), HELZ2 knockdown/overexpression, xenograft mouse model","journal":"Medical oncology (Northwood, London, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus linkage-specific ubiquitination assay and in vivo xenograft, single lab, two orthogonal methods","pmids":["34761308"],"is_preprint":false},{"year":2023,"finding":"HELZ2 inhibits LINE-1 retrotransposition by recognizing sequences and/or structures within the L1 5'UTR, reducing L1 RNA levels, ORF1p protein levels, and ORF1p cytoplasmic foci. HELZ2 overexpression abrogates IFN-α induction caused by L1 overexpression, placing HELZ2 as a suppressor of L1-mediated innate immune activation.","method":"Immunoprecipitation coupled with LC-MS/MS (interactome), retrotransposition assay, immunofluorescence (foci), L1 RNA/protein quantification, IFN-α reporter assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal functional assays (retrotransposition, RNA/protein levels, foci formation, IFN reporter) with mechanistic specificity (5'UTR recognition), peer-reviewed in high-impact journal","pmids":["36639706"],"is_preprint":false},{"year":2023,"finding":"Human HELZ2 is produced from a non-canonical initiation codon in Hominidae, extending the protein by 247 residues at the N-terminus. HELZ2 possesses active 3'-5' exoribonuclease (RNase) activity despite substitution of a canonical catalytic residue in its RNB domain, and can degrade structured RNAs through ATP-dependent RNA helicase activity coupled to its ribonucleolytic activity. HELZ2 RNase activity is lost via somatic mutations in some cancer patients.","method":"Bioinformatics/evolutionary analysis, experimental verification of non-canonical start codon, in vitro ribonuclease activity assay, RNA helicase functional assay (ATP-dependent), analysis of cancer somatic mutations","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution of both RNase and helicase activities with mechanistic dissection, single lab but multiple orthogonal biochemical methods","pmids":["37602378"],"is_preprint":false},{"year":2025,"finding":"HELZ2 binds Apob mRNA and degrades it through its helicase activity, controlling hepatic apoB levels. A gain-of-function mutation (L1833P) enhances HELZ2 helicase activity, markedly reducing Apob mRNA and increasing hepatic lipid accumulation. Helz2-deficient mice show increased Apob mRNA and reduced hepatic triglycerides on high-fat diet.","method":"Forward genetic screen in mutagenized mice, biochemical mRNA binding assay, liver-specific doxycycline-inducible HELZ2 overexpression model, Helz2 knockout mouse analysis, apolipoprotein and lipid measurements, atherosclerosis models (Apoe and Ldlr knockout mice)","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical demonstration of HELZ2 binding to Apob mRNA and its degradation, gain-of-function and loss-of-function mouse models, liver-specific inducible overexpression as orthogonal test, multiple convergent approaches","pmids":["41446920"],"is_preprint":false},{"year":2026,"finding":"HELZ2 interacts with and stabilizes MYC protein; MYC in turn directly activates transcription of ATG16L1, an autophagy-related gene. This HELZ2-MYC-ATG16L1 axis promotes macrophage autophagic flux and intracellular Mycobacterium tuberculosis clearance. HELZ2 silencing impairs phagocytosis, reduces autophagic flux, and increases intracellular Mtb survival.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, gene knockdown/overexpression, bacterial survival assay","journal":"Journal of medical microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, and luciferase reporter together establish the HELZ2-MYC-ATG16L1 axis; single lab, multiple orthogonal methods","pmids":["42262972"],"is_preprint":false},{"year":2026,"finding":"SETD1A-mediated H3K4me3 at the HELZ2 promoter regulates HELZ2 transcription; SETD1A knockdown reduces H3K4me3 enrichment at the HELZ2 promoter, inhibiting HELZ2 expression and disrupting the HELZ2/PPARα complex, which downregulates HIF1α, impairs glycolytic metabolism, and induces nucleus pulposus cell senescence.","method":"ChIP-seq/ChIP-qPCR (H3K4me3), SETD1A knockdown and overexpression in nucleus pulposus cells, human NP tissue analysis, animal model of intervertebral disc degeneration, gene expression analysis","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates epigenetic regulation of HELZ2 promoter; functional rescue experiments link SETD1A→H3K4me3→HELZ2→PPARα→HIF1α axis; single lab","pmids":["41917726"],"is_preprint":false}],"current_model":"HELZ2 is an interferon-stimulated, nuclear-receptor coactivator and RNA-processing enzyme that: (1) functions as a transcriptional coactivator for PPARα and PPARγ by assembling into multiprotein complexes (including THRAP3 and SFPQ) and being co-recruited to PPAR-response elements; (2) acts as an active 3'-5' exoribonuclease whose helicase domains unwind structured RNA substrates for degradation—most critically degrading Apob mRNA to control hepatic lipid homeostasis; (3) inhibits LINE-1 retrotransposition and L1-triggered IFN-α induction by recognizing L1 5'UTR sequences and reducing L1 RNA and ORF1p levels; (4) suppresses dengue virus replication as an IFN antiviral effector, partly through AHR interactions and intracellular lipid modulation; (5) promotes c-Myc/K63-polyubiquitination via HUWE1 in retinoblastoma cells; and (6) stabilizes MYC to drive ATG16L1-mediated macrophage autophagy against Mycobacterium tuberculosis."},"narrative":{"mechanistic_narrative":"HELZ2 is a dual-function protein that operates both as a ligand-dependent nuclear-receptor transcriptional coactivator and as an ATP-dependent 3'-5' exoribonuclease controlling RNA turnover [PMID:12189208, PMID:37602378]. As a coactivator, it was first isolated as a PPARα-interacting cofactor bearing multiple LXXLL motifs that stimulate PPARα-driven transcription [PMID:12189208], and it assembles with the Mediator-associated factor THRAP3 through its helicase motifs to synergistically enhance PPARγ-mediated transcription, being co-recruited with THRAP3 to PPAR-response elements in adipocyte enhancers in a ligand-dependent manner [PMID:23525231]. As an enzyme, HELZ2 possesses bona fide ribonuclease activity from an RNB domain that has lost a canonical catalytic residue, and its ATP-dependent helicase activity unwinds structured RNA for degradation [PMID:37602378]; this activity directly targets Apob mRNA to set hepatic apoB and lipid levels, with a gain-of-function helicase mutation depleting Apob mRNA and a loss-of-function state elevating it [PMID:41446920]. Consistent with these roles in lipid control, Helz2 deficiency in mice de-represses hepatic Leprb expression, activates AMPK, increases fatty-acid β-oxidation, and protects against diet-induced obesity and insulin resistance [PMID:25004093]. HELZ2 is an interferon-stimulated antiviral effector that suppresses dengue virus replication and modulates intracellular triglyceride pools [PMID:28265266], and it restricts LINE-1 retrotransposition by recognizing the L1 5'UTR to lower L1 RNA and ORF1p and to dampen L1-triggered IFN-α induction [PMID:36639706]. Beyond its transcriptional and RNA-degrading functions, HELZ2 acts in protein-stability pathways: it promotes HUWE1-dependent K63-linked polyubiquitination of c-Myc to drive retinoblastoma proliferation [PMID:34761308] and stabilizes MYC to upregulate ATG16L1-mediated macrophage autophagy against Mycobacterium tuberculosis [PMID:42262972].","teleology":[{"year":2002,"claim":"Established HELZ2's first molecular identity by showing it is a nuclear-receptor coactivator, answering whether the protein has any defined transcriptional role.","evidence":"Biochemical purification of a PPARα-interacting cofactor complex from rat liver, MS identification, and reporter assays","pmids":["12189208"],"confidence":"Medium","gaps":["Coactivation effect was only moderate","Did not address whether HELZ2 has enzymatic activity","Mechanism of recruitment to chromatin not defined"]},{"year":2013,"claim":"Defined how HELZ2 is integrated into the transcriptional machinery by identifying THRAP3 as a helicase-motif partner co-recruited to PPARγ enhancers, explaining ligand-dependent coactivation.","evidence":"Yeast two-hybrid, reciprocal Co-IP/MS, ChIP, reporter assays and siRNA in 3T3-L1 adipocytes","pmids":["23525231"],"confidence":"High","gaps":["Did not test whether helicase catalytic activity is required for coactivation","Endogenous complex stoichiometry unresolved"]},{"year":2014,"claim":"Demonstrated an in vivo metabolic consequence of HELZ2 by showing its loss de-represses hepatic Leprb and protects from obesity, linking the coregulator to systemic lipid homeostasis.","evidence":"Helz2 knockout mice with calorimetry and adenoviral Leprb rescue","pmids":["25004093"],"confidence":"Medium","gaps":["Did not distinguish transcriptional from RNA-degrading mechanism for Leprb control","Direct binding to Leprb locus or transcript not shown"]},{"year":2017,"claim":"Placed HELZ2 in innate antiviral defense as an interferon-stimulated gene restricting dengue virus, expanding its role beyond metabolism.","evidence":"siRNA screen, Co-IP with AHR, ChIP-seq, lipid profiling, and KO mouse macrophage infection assays","pmids":["28265266"],"confidence":"Medium","gaps":["Mechanistic link between AHR interaction, lipid changes, and viral restriction unresolved","Whether RNase activity drives restriction not tested"]},{"year":2021,"claim":"Probed HELZ2's role in adipogenesis by identifying SFPQ as a phospho-HELZ2-associated factor, raising a candidate RNA-binding partner in differentiation control.","evidence":"Co-IP of tyrosine-phosphorylated HELZ2 with MS and siRNA in 3T3-L1 cells","pmids":["34052659"],"confidence":"Low","gaps":["Single Co-IP/MS without reciprocal validation","Functional adipogenesis effects attributed to SFPQ knockdown without direct mechanistic link to HELZ2","Significance of HELZ2 tyrosine phosphorylation unknown"]},{"year":2021,"claim":"Revealed a non-transcriptional protein-stability function by showing HELZ2 bridges c-Myc to HUWE1 for activating K63-linked ubiquitination, connecting HELZ2 to oncogenic proliferation.","evidence":"Co-IP, linkage-specific ubiquitination assays, and retinoblastoma xenografts","pmids":["34761308"],"confidence":"Medium","gaps":["Structural basis of the HELZ2-Myc-HUWE1 bridge unknown","Whether helicase/RNase domains participate not addressed"]},{"year":2023,"claim":"Defined HELZ2 as a genome-defense factor by showing it recognizes the L1 5'UTR to suppress retrotransposition and L1-driven IFN-α, linking RNA recognition to innate immune restraint.","evidence":"IP-LC-MS/MS interactome, retrotransposition assays, RNA/protein quantification, foci imaging, and IFN-α reporters","pmids":["36639706"],"confidence":"High","gaps":["Precise 5'UTR sequence/structure determinant not fully mapped","Whether degradation is catalytic or sequestration not resolved here"]},{"year":2023,"claim":"Resolved HELZ2's enzymatic identity by reconstituting active 3'-5' exoribonuclease and ATP-dependent helicase activities, establishing it as a structured-RNA-degrading enzyme despite a non-canonical RNB catalytic site.","evidence":"Evolutionary analysis, non-canonical start-codon verification, in vitro RNase and helicase assays, and cancer somatic mutation analysis","pmids":["37602378"],"confidence":"High","gaps":["Physiological RNA substrates not defined in this study","Structural mechanism of catalysis with substituted residue unresolved"]},{"year":2025,"claim":"Identified the first defined physiological RNA substrate by showing HELZ2 binds and degrades Apob mRNA to control hepatic lipid levels, unifying its RNase/helicase activity with its metabolic phenotypes.","evidence":"Forward genetic screen in mice, mRNA binding assays, inducible liver overexpression, KO mice, and atherosclerosis models","pmids":["41446920"],"confidence":"High","gaps":["Whether other lipid-related transcripts are direct substrates unknown","Relationship between Apob-degrading and coactivator functions unresolved"]},{"year":2026,"claim":"Extended the HELZ2-MYC axis to host defense by showing HELZ2 stabilizes MYC to activate ATG16L1 transcription and macrophage autophagy against M. tuberculosis.","evidence":"Co-IP, ChIP, dual-luciferase reporters, knockdown/overexpression, and bacterial survival assays","pmids":["42262972"],"confidence":"Medium","gaps":["Mechanism of MYC stabilization (vs. the prior K63-ubiquitination model) not reconciled","Direct vs. indirect role of HELZ2 enzymatic domains untested"]},{"year":2026,"claim":"Defined upstream control of HELZ2 by showing SETD1A-deposited H3K4me3 drives HELZ2 transcription, with the HELZ2/PPARα complex feeding into HIF1α-dependent glycolysis and cellular senescence.","evidence":"ChIP-seq/qPCR for H3K4me3, SETD1A knockdown/overexpression, NP tissue and disc degeneration models","pmids":["41917726"],"confidence":"Medium","gaps":["Direct HELZ2-HIF1α regulatory mechanism not shown","Whether RNase activity participates in NP senescence untested"]},{"year":null,"claim":"How HELZ2's distinct activities — nuclear-receptor coactivation, structured-RNA degradation, and MYC stabilization — are coordinated within one protein and selected in different cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating helicase, RNB, and coactivator modules","Full physiological RNA substrate repertoire unknown","Domain requirements for the protein-stability functions undetermined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[7,8]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[7,8]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[7,8]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,2]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[7,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,6]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,8]}],"complexes":["PRIC (PPARα-interacting cofactor) complex"],"partners":["PPARA","PPARG","THRAP3","SFPQ","AHR","MYC","HUWE1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BYK8","full_name":"3'-5' exoribonuclease HELZ2","aliases":["ATP-dependent RNA helicase PRIC285","Helicase with zinc finger 2, transcriptional coactivator","Helicase with zinc finger domain 2","PPAR-alpha-interacting complex protein 285","PPAR-gamma DNA-binding domain-interacting protein 1","PDIP1","PPAR-gamma DBD-interacting protein 1","Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein"],"length_aa":2896,"mass_kda":322.3,"function":"Can degrade highly structured RNAs through its concerted ATP-dependent RNA helicase and 3' to 5' exoribonuclease activities (PubMed:37602378). Shows a strong preference for pyrimidine over purine residues for its nuclease activity (PubMed:37602378). Acts as a transcriptional coactivator for a number of nuclear receptors including PPARA, PPARG, THRA, THRB and RXRA (PubMed:16239304, PubMed:23525231)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9BYK8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HELZ2","classification":"Not Classified","n_dependent_lines":22,"n_total_lines":1208,"dependency_fraction":0.018211920529801324},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"PACSIN2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HELZ2","total_profiled":1310},"omim":[],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HELZ2"},"hgnc":{"alias_symbol":["PDIP1","PRIC285","KIAA1769"],"prev_symbol":[]},"alphafold":{"accession":"Q9BYK8","domains":[{"cath_id":"2.60.40.2310","chopping":"152-276","consensus_level":"medium","plddt":78.621,"start":152,"end":276},{"cath_id":"-","chopping":"288-324_386-488","consensus_level":"medium","plddt":75.241,"start":288,"end":488},{"cath_id":"3.40.50.300","chopping":"501-740","consensus_level":"high","plddt":82.8548,"start":501,"end":740},{"cath_id":"3.40.50.300","chopping":"775-960","consensus_level":"high","plddt":77.2995,"start":775,"end":960},{"cath_id":"2.40.50.690","chopping":"1111-1200","consensus_level":"medium","plddt":78.2301,"start":1111,"end":1200},{"cath_id":"2.40.50,2.40.50","chopping":"1202-1289","consensus_level":"medium","plddt":80.4405,"start":1202,"end":1289},{"cath_id":"2.40.30.230","chopping":"1967-2017_2036-2051_2064-2097","consensus_level":"medium","plddt":82.9889,"start":1967,"end":2097},{"cath_id":"3.40.50.300","chopping":"2144-2198_2213-2259_2274-2424","consensus_level":"medium","plddt":85.7391,"start":2144,"end":2424},{"cath_id":"3.40.50.300","chopping":"2438-2642","consensus_level":"high","plddt":85.9619,"start":2438,"end":2642}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYK8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYK8-2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BYK8-2-F1-predicted_aligned_error_v6.png","plddt_mean":80.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HELZ2","jax_strain_url":"https://www.jax.org/strain/search?query=HELZ2"},"sequence":{"accession":"Q9BYK8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BYK8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BYK8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BYK8"}},"corpus_meta":[{"pmid":"12189208","id":"PMC_12189208","title":"Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12189208","citation_count":118,"is_preprint":false},{"pmid":"23525231","id":"PMC_23525231","title":"THRAP3 interacts with HELZ2 and plays a novel role in adipocyte differentiation.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23525231","citation_count":35,"is_preprint":false},{"pmid":"28265266","id":"PMC_28265266","title":"HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus.","date":"2017","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28265266","citation_count":35,"is_preprint":false},{"pmid":"36639706","id":"PMC_36639706","title":"The interferon stimulated gene-encoded protein HELZ2 inhibits human LINE-1 retrotransposition and LINE-1 RNA-mediated type I interferon induction.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36639706","citation_count":25,"is_preprint":false},{"pmid":"25004093","id":"PMC_25004093","title":"Protection against high-fat diet-induced obesity in Helz2-deficient male mice due to enhanced expression of hepatic leptin receptor.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25004093","citation_count":18,"is_preprint":false},{"pmid":"37602378","id":"PMC_37602378","title":"HELZ2: a new, interferon-regulated, human 3'-5' exoribonuclease of the RNB family is expressed from a non-canonical initiation codon.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37602378","citation_count":12,"is_preprint":false},{"pmid":"27047549","id":"PMC_27047549","title":"A rare nonsynonymous variant in the lipid metabolic gene HELZ2 related to primary biliary cirrhosis in Chinese Han.","date":"2016","source":"Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27047549","citation_count":8,"is_preprint":false},{"pmid":"34761308","id":"PMC_34761308","title":"HELZ2 promotes K63-linked polyubiquitination of c-Myc to induce retinoblastoma tumorigenesis.","date":"2021","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34761308","citation_count":7,"is_preprint":false},{"pmid":"34052659","id":"PMC_34052659","title":"SFPQ associated with a co-activator for PPARγ, HELZ2, regulates key nuclear factors for adipocyte differentiation.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34052659","citation_count":4,"is_preprint":false},{"pmid":"41446920","id":"PMC_41446920","title":"HELZ2 Regulates Apob mRNA Stability to Modulate Fatty Liver Disease and Atherosclerosis.","date":"2025","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/41446920","citation_count":0,"is_preprint":false},{"pmid":"41917726","id":"PMC_41917726","title":"SETD1A Regulates Glycolysis and Senescence of Nucleus Pulposus Cells via H3K4me3-HELZ2/PPARα-HIF1α Axis to Drive Intervertebral Disc Degeneration.","date":"2026","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41917726","citation_count":0,"is_preprint":false},{"pmid":"42262972","id":"PMC_42262972","title":"Eliminate Mycobacterium tuberculosis via HELZ2 and up-regulating ATG16L1 to promote macrophage autophagy.","date":"2026","source":"Journal of medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/42262972","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.26.645456","title":"12/15-Lipoxygenase orchestrates murine wound healing via PPARγ-activating oxylipins acting holistically to dampen inflammation","date":"2025-03-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.26.645456","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10075,"output_tokens":3372,"usd":0.040403,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10971,"output_tokens":4076,"usd":0.078378,"stage2_stop_reason":"end_turn"},"total_usd":0.118781,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"PRIC285 (HELZ2) was identified as a component of a transcriptionally active PPARα-interacting cofactor (PRIC) complex purified from rat liver nuclear extracts. PRIC285 contains five LXXLL motifs, interacts with PPARα, and acts as a coactivator by moderately stimulating PPARα-mediated transcription in transfected cells.\",\n      \"method\": \"Biochemical purification of nuclear extract complex, mass spectrometry, limited sequence analysis, cDNA cloning, transfection-based reporter assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complex purification with MS identification plus functional reporter assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"12189208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HELZ2 interacts with THRAP3 (a Mediator complex component) via its helicase motifs; THRAP3 and HELZ2 synergistically enhance PPARγ-mediated transcription, and both are co-recruited to PPARγ-response elements in the Fabp4/aP2 and Adipoq gene enhancers in a ligand-dependent manner in differentiated 3T3-L1 adipocytes.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation with mass spectrometry, reporter assay, siRNA knockdown, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP, reporter assay, and siRNA rescue all converge on the same mechanism; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"23525231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HELZ2 functions as an interferon (IFN) antiviral effector (IFN-stimulated gene) against dengue virus; upon IFN stimulation, HELZ2 protein levels increase in the nucleus. HELZ2 interacts with the aryl hydrocarbon receptor (AHR) as identified by co-immunoprecipitation, and HELZ2 knockdown cells are depleted of specific triglyceride subsets. Primary macrophages from HELZ2 knockout mice show enhanced dengue infectivity compared to wild-type controls.\",\n      \"method\": \"Functional genomic screen (siRNA), co-immunoprecipitation, ChIP-sequencing, mass spectrometry (lipid profiling), HELZ2 knockout mouse macrophage infection assay\",\n      \"journal\": \"Frontiers in microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse experiment with defined infectious phenotype plus Co-IP and ChIP-seq, single lab, multiple methods\",\n      \"pmids\": [\"28265266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Helz2 deficiency in mice leads to upregulated hepatic Leprb (long-form leptin receptor) expression, activation of hepatic AMPK, increased fatty acid β-oxidation, and protection from high-fat diet-induced obesity and insulin resistance, establishing HELZ2 as a transcriptional coregulator that suppresses hepatic Leprb expression in vivo.\",\n      \"method\": \"Helz2 knockout mouse generation and phenotypic analysis, adenovirus-mediated liver-specific Leprb overexpression, calorimetry, gene expression analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with defined metabolic phenotype and rescue experiment (adenoviral Leprb), single lab\",\n      \"pmids\": [\"25004093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SFPQ associates with tyrosine-phosphorylated HELZ2 as identified by co-immunoprecipitation and mass spectrometry; SFPQ knockdown in 3T3-L1 cells downregulates early adipocyte differentiation transcription factors (Krox20, C/EBPβ, C/EBPδ) and inhibits adipocyte differentiation.\",\n      \"method\": \"Co-immunoprecipitation of phospho-HELZ2 followed by mass spectrometry, siRNA knockdown, gene expression analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP/MS identification of SFPQ interaction, functional effects attributed to SFPQ knockdown without direct mechanistic link to HELZ2\",\n      \"pmids\": [\"34052659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HELZ2 interacts with c-Myc and promotes its K63-linked polyubiquitination by facilitating the interaction between c-Myc and E3 ubiquitin ligase HUWE1; this HUWE1-dependent K63-linked ubiquitination activates c-Myc and promotes retinoblastoma cell proliferation and tumorigenesis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K63-linkage specific), HELZ2 knockdown/overexpression, xenograft mouse model\",\n      \"journal\": \"Medical oncology (Northwood, London, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus linkage-specific ubiquitination assay and in vivo xenograft, single lab, two orthogonal methods\",\n      \"pmids\": [\"34761308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HELZ2 inhibits LINE-1 retrotransposition by recognizing sequences and/or structures within the L1 5'UTR, reducing L1 RNA levels, ORF1p protein levels, and ORF1p cytoplasmic foci. HELZ2 overexpression abrogates IFN-α induction caused by L1 overexpression, placing HELZ2 as a suppressor of L1-mediated innate immune activation.\",\n      \"method\": \"Immunoprecipitation coupled with LC-MS/MS (interactome), retrotransposition assay, immunofluorescence (foci), L1 RNA/protein quantification, IFN-α reporter assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal functional assays (retrotransposition, RNA/protein levels, foci formation, IFN reporter) with mechanistic specificity (5'UTR recognition), peer-reviewed in high-impact journal\",\n      \"pmids\": [\"36639706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Human HELZ2 is produced from a non-canonical initiation codon in Hominidae, extending the protein by 247 residues at the N-terminus. HELZ2 possesses active 3'-5' exoribonuclease (RNase) activity despite substitution of a canonical catalytic residue in its RNB domain, and can degrade structured RNAs through ATP-dependent RNA helicase activity coupled to its ribonucleolytic activity. HELZ2 RNase activity is lost via somatic mutations in some cancer patients.\",\n      \"method\": \"Bioinformatics/evolutionary analysis, experimental verification of non-canonical start codon, in vitro ribonuclease activity assay, RNA helicase functional assay (ATP-dependent), analysis of cancer somatic mutations\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution of both RNase and helicase activities with mechanistic dissection, single lab but multiple orthogonal biochemical methods\",\n      \"pmids\": [\"37602378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HELZ2 binds Apob mRNA and degrades it through its helicase activity, controlling hepatic apoB levels. A gain-of-function mutation (L1833P) enhances HELZ2 helicase activity, markedly reducing Apob mRNA and increasing hepatic lipid accumulation. Helz2-deficient mice show increased Apob mRNA and reduced hepatic triglycerides on high-fat diet.\",\n      \"method\": \"Forward genetic screen in mutagenized mice, biochemical mRNA binding assay, liver-specific doxycycline-inducible HELZ2 overexpression model, Helz2 knockout mouse analysis, apolipoprotein and lipid measurements, atherosclerosis models (Apoe and Ldlr knockout mice)\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical demonstration of HELZ2 binding to Apob mRNA and its degradation, gain-of-function and loss-of-function mouse models, liver-specific inducible overexpression as orthogonal test, multiple convergent approaches\",\n      \"pmids\": [\"41446920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"HELZ2 interacts with and stabilizes MYC protein; MYC in turn directly activates transcription of ATG16L1, an autophagy-related gene. This HELZ2-MYC-ATG16L1 axis promotes macrophage autophagic flux and intracellular Mycobacterium tuberculosis clearance. HELZ2 silencing impairs phagocytosis, reduces autophagic flux, and increases intracellular Mtb survival.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, gene knockdown/overexpression, bacterial survival assay\",\n      \"journal\": \"Journal of medical microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, and luciferase reporter together establish the HELZ2-MYC-ATG16L1 axis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"42262972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SETD1A-mediated H3K4me3 at the HELZ2 promoter regulates HELZ2 transcription; SETD1A knockdown reduces H3K4me3 enrichment at the HELZ2 promoter, inhibiting HELZ2 expression and disrupting the HELZ2/PPARα complex, which downregulates HIF1α, impairs glycolytic metabolism, and induces nucleus pulposus cell senescence.\",\n      \"method\": \"ChIP-seq/ChIP-qPCR (H3K4me3), SETD1A knockdown and overexpression in nucleus pulposus cells, human NP tissue analysis, animal model of intervertebral disc degeneration, gene expression analysis\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates epigenetic regulation of HELZ2 promoter; functional rescue experiments link SETD1A→H3K4me3→HELZ2→PPARα→HIF1α axis; single lab\",\n      \"pmids\": [\"41917726\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HELZ2 is an interferon-stimulated, nuclear-receptor coactivator and RNA-processing enzyme that: (1) functions as a transcriptional coactivator for PPARα and PPARγ by assembling into multiprotein complexes (including THRAP3 and SFPQ) and being co-recruited to PPAR-response elements; (2) acts as an active 3'-5' exoribonuclease whose helicase domains unwind structured RNA substrates for degradation—most critically degrading Apob mRNA to control hepatic lipid homeostasis; (3) inhibits LINE-1 retrotransposition and L1-triggered IFN-α induction by recognizing L1 5'UTR sequences and reducing L1 RNA and ORF1p levels; (4) suppresses dengue virus replication as an IFN antiviral effector, partly through AHR interactions and intracellular lipid modulation; (5) promotes c-Myc/K63-polyubiquitination via HUWE1 in retinoblastoma cells; and (6) stabilizes MYC to drive ATG16L1-mediated macrophage autophagy against Mycobacterium tuberculosis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HELZ2 is a dual-function protein that operates both as a ligand-dependent nuclear-receptor transcriptional coactivator and as an ATP-dependent 3'-5' exoribonuclease controlling RNA turnover [#0, #7]. As a coactivator, it was first isolated as a PPARα-interacting cofactor bearing multiple LXXLL motifs that stimulate PPARα-driven transcription [#0], and it assembles with the Mediator-associated factor THRAP3 through its helicase motifs to synergistically enhance PPARγ-mediated transcription, being co-recruited with THRAP3 to PPAR-response elements in adipocyte enhancers in a ligand-dependent manner [#1]. As an enzyme, HELZ2 possesses bona fide ribonuclease activity from an RNB domain that has lost a canonical catalytic residue, and its ATP-dependent helicase activity unwinds structured RNA for degradation [#7]; this activity directly targets Apob mRNA to set hepatic apoB and lipid levels, with a gain-of-function helicase mutation depleting Apob mRNA and a loss-of-function state elevating it [#8]. Consistent with these roles in lipid control, Helz2 deficiency in mice de-represses hepatic Leprb expression, activates AMPK, increases fatty-acid β-oxidation, and protects against diet-induced obesity and insulin resistance [#3]. HELZ2 is an interferon-stimulated antiviral effector that suppresses dengue virus replication and modulates intracellular triglyceride pools [#2], and it restricts LINE-1 retrotransposition by recognizing the L1 5'UTR to lower L1 RNA and ORF1p and to dampen L1-triggered IFN-α induction [#6]. Beyond its transcriptional and RNA-degrading functions, HELZ2 acts in protein-stability pathways: it promotes HUWE1-dependent K63-linked polyubiquitination of c-Myc to drive retinoblastoma proliferation [#5] and stabilizes MYC to upregulate ATG16L1-mediated macrophage autophagy against Mycobacterium tuberculosis [#9].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established HELZ2's first molecular identity by showing it is a nuclear-receptor coactivator, answering whether the protein has any defined transcriptional role.\",\n      \"evidence\": \"Biochemical purification of a PPARα-interacting cofactor complex from rat liver, MS identification, and reporter assays\",\n      \"pmids\": [\"12189208\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Coactivation effect was only moderate\", \"Did not address whether HELZ2 has enzymatic activity\", \"Mechanism of recruitment to chromatin not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined how HELZ2 is integrated into the transcriptional machinery by identifying THRAP3 as a helicase-motif partner co-recruited to PPARγ enhancers, explaining ligand-dependent coactivation.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP/MS, ChIP, reporter assays and siRNA in 3T3-L1 adipocytes\",\n      \"pmids\": [\"23525231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test whether helicase catalytic activity is required for coactivation\", \"Endogenous complex stoichiometry unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated an in vivo metabolic consequence of HELZ2 by showing its loss de-represses hepatic Leprb and protects from obesity, linking the coregulator to systemic lipid homeostasis.\",\n      \"evidence\": \"Helz2 knockout mice with calorimetry and adenoviral Leprb rescue\",\n      \"pmids\": [\"25004093\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not distinguish transcriptional from RNA-degrading mechanism for Leprb control\", \"Direct binding to Leprb locus or transcript not shown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed HELZ2 in innate antiviral defense as an interferon-stimulated gene restricting dengue virus, expanding its role beyond metabolism.\",\n      \"evidence\": \"siRNA screen, Co-IP with AHR, ChIP-seq, lipid profiling, and KO mouse macrophage infection assays\",\n      \"pmids\": [\"28265266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between AHR interaction, lipid changes, and viral restriction unresolved\", \"Whether RNase activity drives restriction not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Probed HELZ2's role in adipogenesis by identifying SFPQ as a phospho-HELZ2-associated factor, raising a candidate RNA-binding partner in differentiation control.\",\n      \"evidence\": \"Co-IP of tyrosine-phosphorylated HELZ2 with MS and siRNA in 3T3-L1 cells\",\n      \"pmids\": [\"34052659\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single Co-IP/MS without reciprocal validation\", \"Functional adipogenesis effects attributed to SFPQ knockdown without direct mechanistic link to HELZ2\", \"Significance of HELZ2 tyrosine phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a non-transcriptional protein-stability function by showing HELZ2 bridges c-Myc to HUWE1 for activating K63-linked ubiquitination, connecting HELZ2 to oncogenic proliferation.\",\n      \"evidence\": \"Co-IP, linkage-specific ubiquitination assays, and retinoblastoma xenografts\",\n      \"pmids\": [\"34761308\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the HELZ2-Myc-HUWE1 bridge unknown\", \"Whether helicase/RNase domains participate not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined HELZ2 as a genome-defense factor by showing it recognizes the L1 5'UTR to suppress retrotransposition and L1-driven IFN-α, linking RNA recognition to innate immune restraint.\",\n      \"evidence\": \"IP-LC-MS/MS interactome, retrotransposition assays, RNA/protein quantification, foci imaging, and IFN-α reporters\",\n      \"pmids\": [\"36639706\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise 5'UTR sequence/structure determinant not fully mapped\", \"Whether degradation is catalytic or sequestration not resolved here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved HELZ2's enzymatic identity by reconstituting active 3'-5' exoribonuclease and ATP-dependent helicase activities, establishing it as a structured-RNA-degrading enzyme despite a non-canonical RNB catalytic site.\",\n      \"evidence\": \"Evolutionary analysis, non-canonical start-codon verification, in vitro RNase and helicase assays, and cancer somatic mutation analysis\",\n      \"pmids\": [\"37602378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological RNA substrates not defined in this study\", \"Structural mechanism of catalysis with substituted residue unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified the first defined physiological RNA substrate by showing HELZ2 binds and degrades Apob mRNA to control hepatic lipid levels, unifying its RNase/helicase activity with its metabolic phenotypes.\",\n      \"evidence\": \"Forward genetic screen in mice, mRNA binding assays, inducible liver overexpression, KO mice, and atherosclerosis models\",\n      \"pmids\": [\"41446920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other lipid-related transcripts are direct substrates unknown\", \"Relationship between Apob-degrading and coactivator functions unresolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Extended the HELZ2-MYC axis to host defense by showing HELZ2 stabilizes MYC to activate ATG16L1 transcription and macrophage autophagy against M. tuberculosis.\",\n      \"evidence\": \"Co-IP, ChIP, dual-luciferase reporters, knockdown/overexpression, and bacterial survival assays\",\n      \"pmids\": [\"42262972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of MYC stabilization (vs. the prior K63-ubiquitination model) not reconciled\", \"Direct vs. indirect role of HELZ2 enzymatic domains untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined upstream control of HELZ2 by showing SETD1A-deposited H3K4me3 drives HELZ2 transcription, with the HELZ2/PPARα complex feeding into HIF1α-dependent glycolysis and cellular senescence.\",\n      \"evidence\": \"ChIP-seq/qPCR for H3K4me3, SETD1A knockdown/overexpression, NP tissue and disc degeneration models\",\n      \"pmids\": [\"41917726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HELZ2-HIF1α regulatory mechanism not shown\", \"Whether RNase activity participates in NP senescence untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HELZ2's distinct activities — nuclear-receptor coactivation, structured-RNA degradation, and MYC stabilization — are coordinated within one protein and selected in different cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating helicase, RNB, and coactivator modules\", \"Full physiological RNA substrate repertoire unknown\", \"Domain requirements for the protein-stability functions undetermined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 6]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 8]}\n    ],\n    \"complexes\": [\n      \"PRIC (PPARα-interacting cofactor) complex\"\n    ],\n    \"partners\": [\n      \"PPARA\",\n      \"PPARG\",\n      \"THRAP3\",\n      \"SFPQ\",\n      \"AHR\",\n      \"MYC\",\n      \"HUWE1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}